100
Participants
Start Date
May 31, 2014
Primary Completion Date
August 28, 2019
Study Completion Date
August 28, 2019
Nintedanib
Nintedanib should be administered orally at a dose of 200 mg twice daily.
Placebo
Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet, Brussels
Cliniques Universitaires Saint-Luc, Brussels
Leiden University Medical Centre, Leiden
Universitair Ziekenhuis Antwerpen, Edegem, Antwerpen
U.Z. Leuven - Campus Gasthuisberg, Leuven
Odense University Hospital, Odense
Radboud University Medical Center Nijmegen, Nijmegen
A.Z. St. Jan, Bruges
Universitair Ziekenhuis Gent, Ghent
University Medical Center Groningen, Groningen
Centre Regional Francois Baclesse, Caen
Centre Georges-Francois-Leclerc, Dijon
Institut Bergonie, Bordeaux
CHU d'Angers, Angers
Centre Jean Godinot, Reims
Centre Leon Berard, Lyon
Assitance Publique - Hopitaux de Paris - Hopital Saint-Louis, Paris
Assistance Publique - Hopitaux de Paris - La Pitié Salpétrière, Paris
"Azienda Ospedaliera Universitaria Federico II", Napoli
Institut Gustave Roussy, Villejuif
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Ludwig-Maximilians-Universitaet Muenchen - Klinikum der Universitaet Muenchen - Campus Grosshadern, Munich
Universitaetsklinikum Wuerzburg, Würzburg
Maria Sklodowska-Curie Memorial Cancer Centre, Warsaw
Hospital General Vall D'Hebron, Barcelona
Royal Marsden Hospital - Sutton, Surrey, Sutton
NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital, Glasgow
European Organisation for Research and Treatment of Cancer - EORTC
NETWORK